Nick Veomett
Vice President, Corporate Development & Program Lead Artiva Biotherapeutics
Nicholas Veomett is Vice President of Corporate Development at Artiva Biotherapeutics, a clinical-stage company developing off-the-shelf natural killer (NK) cell therapies for autoimmune disease and cancer. Since joining Artiva in 2021, he has led strategic initiatives, including the advancement of AlloNK®, which has demonstrated clinical activity and tolerability in B-cell NHL, and is currently in clinical trials for autoimmune indications including RA, Sjögren’s disease, myositis, systemic sclerosis, and SLE/LN. Previously, Dr. Veomett held corporate development roles at Vividion Therapeutics and was an Engagement Manager at McKinsey & Company. He earned his Ph.D. in Pharmacology from Weill Cornell Medical College, with research at the Sloan Kettering Institute.
Seminars
- Profile of AlloNK, ability to deeply deplete B-cells, and potential advantages over other modalities
- Early clinical insights from ongoing clinical trials in autoimmune disease
- Process strategies enabling consistency and potency at scale
